Document is current
Any future updates will be listed below
-
Authors
Simpson, Eric L. https://orcid.org/0000-0003-0853-0252
Bissonnette, Robert https://orcid.org/0000-0001-5927-6587
Deleuran, Mette https://orcid.org/0000-0003-0593-9925
Nakahara, Takeshi https://orcid.org/0000-0003-2811-8273
Galus, Ryszard https://orcid.org/0000-0002-2826-7896
de Bruin-Weller, Marjolein https://orcid.org/0000-0002-1249-6993
Coleman, Anna
van Spall, Michael
Chen, Zhen
Avetisova, Elena
Bastian, Mike https://orcid.org/0000-0001-8347-7426
Khokhar, Faisal A.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01949311 at ClinicalTrials.govnct02260986 at ClinicalTrials.govDocuments that mention this clinical trial
Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
https://doi.org/10.1007/s13555-021-00643-4
Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis
https://doi.org/10.1007/s13555-021-00630-9
Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s12325-025-03458-3
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s40257-022-00685-0
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
https://doi.org/10.1016/s0140-6736(15)00388-8
Documents that mention this clinical trial
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
https://doi.org/10.1007/s13555-021-00657-y
Identifying the Most Relevant Eczema Area and Severity Index Thresholds from the Patient Perspective in Atopic Dermatitis Treatment
https://doi.org/10.1007/s40257-026-01017-2
Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s12325-025-03458-3
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
https://doi.org/10.1016/s0140-6736(15)00388-8
Optimal Itch Response in Adults Treated with Dupilumab for Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-025-01519-7
Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial
https://doi.org/10.1007/s13555-021-00487-y
Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial
https://doi.org/10.1007/s13555-020-00456-x
-
Funding
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals
- License Information
-
More Information
Article History
Received: 4 September 2025
Accepted: 28 November 2025
First Online: 21 January 2026
Declarations
:
: Eric L. Simpson is a principal investigator or has received grants from AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, CorEvitas, Dermavant, Dermira, Eli Lilly, Incyte, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, Target, and Veriskin; and has received personal fess from AbbVie, Amgen, Arcutis, Astria Therapeutics, Castle, CorEvitas, Dermira, Eli Lilly, FIDE, Impetus Healthcare, Incyte, Innovaderm Recherches/Indero, Janssen, LEO Pharma, Numab Therapeutics AG, Pfizer, Recludix Pharma, Regeneron Pharmaceuticals Inc., Roche Products Ltd, Sanofi, and Sitryx Therapeutics. Robert Bissonnette is a consultant and has received grants/research support from AbbVie, Aclaris Therapeutics, Alumis, Amgen, Apogee Therapeutics, Arcutis Biotherapeutics, Areteia Therapeutics, Asana BioSciences, Attovia, BELLUS Health, BioMimetix, Bluefin Biomedicine, Boehringer Ingelheim, Boston Pharmaceuticals, Cara Therapeutics, Dermavant, Eli Lilly, Escient Pharmaceuticals, Evidera, Fresh Tracks Therapeutics (formerly Brickell Biotech), Galderma, GSK, Incyte, Inmagene Biopharmaceuticals, Janssen, LEO Pharma, Merck, Novartis, OPSIDIO, Pfizer, RAPT Therapeutics, Sanofi, Sitryx Therapeutics, Target RWE, VYNE Therapeutics, and Zencor; and is a shareholder of Innovaderm Research. Mette Deleuran has received research support/consulting fees/advisory board agreements, travel support, and/or honoraria for lectures from AbbVie, Almirall, Eli Lilly, Incyte, Kymab, La Roche-Posay, LEO Pharma, Mustela, Numab, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals Inc., and Sanofi, and Union Therapeutics. Takeshi Nakahara has received laboratory funds from Maruho; and speaker fees from Maruho and Sanofi. Ryszard Galus is an investigator for and has received consulting fees from Amgen, Boehringer Ingelheim, Chugai, Dermira, Evelo Biosciences, Galderma, Glenmark, Incyte, Janssen, Kymab, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, and UCB. Marjolein de Bruin-Weller is a consultant, advisory board member, and/or speaker for AbbVie, Almirall, Eli Lilly, Galderma, Janssen, LEO Pharma, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, and UCB. Michael van Spall and Mike Bastian are employees of Sanofi and may hold stock and/or stock options in the company. Anna Coleman, Zhen Chen, Elena Avetisova, and Faisal A. Khokhar are employees and shareholders of Regeneron Pharmaceuticals Inc.
: The study was conducted following ethical principles derived from the Declaration of Helsinki, the International Conference for Harmonisation guideline, Good Clinical Practice guidelines, and applicable local regulatory requirements. The protocol was reviewed and approved by institutional review boards/ethics committees at all centers. Written informed consent was obtained from all patients prior to commencement of any study procedures. A list of study investigators and a list of institutional review boards/ethics committees are available in the supplemental materials (Table and Table , respectively).
